Drug Stock Index Reaches New High Amid Trade Truce Skepticism
(Bloomberg) -- The S&P 500 Pharmaceuticals Index rose as much as 1 percent to a record high, skirting a broad market sell-off as investors continued to shift into the high-momentum sector amid skepticism about the trade truce between the U.S. and China.
- Merck and Pfizer, which have been added to the closely watched $9.4b iShares Edge MSCI USA Momentum ETF in its latest rebalance, are among today's top performers
- Mutual funds and hedge funds have also increased their exposure to health care into the fourth quarter, according to data from Goldman Sachs, with pharma accounting for the largest increase in allocations from mutual funds
- The most "crowded" biopharma-longs for these funds include AMGN, BIIB, LLY and VRTX, Goldman analyst Asad Haider wrote in a note last week
- The momentum in pharmaceutical stocks has accelerated since mid-July as investors sought havens from the trade war with China and appetite for growth tech shares waned
- Biotechnology stocks, which are typically seen as a barometer for risk appetite, are rebounding from their worst monthly drop in October since early 2016; the Nasdaq Biotech index rose as much as 0.9% today
- The S&P 500 Health index remains the top-performing sector in the S&P 500 this year, up 15%
To contact the reporter on this story: Tatiana Darie in New York at tdarie1@bloomberg.net
To contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Richard Richtmyer
©2018 Bloomberg L.P.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
